Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transactivation

Cancer Biology and Therapy

Volumn 8, Issue 10, 2009, Pages 890-898

  Ratanaphan, Adisorn ^a,b   Wasiksiri, Siriwat ^a,b   Canyuk, Bhutorn ^a   Prasertsan, Poonsuk ^b  

^a Faculty of Pharmaceutical Sciences   (Thailand)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

BRCA1; Cisplatin; DNA damage; DNA repair; DSC; Luciferase activity; Thermal stability; Transcriptional transactivation

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; PLASMID DNA; RESTRICTION ENDONUCLEASE; TRANSCRIPTION FACTOR GAL4;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DNA REPAIR; EXPRESSION VECTOR; GENE SEQUENCE; HOST CELL; HUMAN; HUMAN CELL; REPORTER GENE; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; THERMOGRAPHY; THERMOSTABILITY; TRANSCRIPTION INITIATION; TRANSITION TEMPERATURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, BRCA1; GENES, REPORTER; HUMANS; LUCIFERASES, RENILLA; PLASMIDS; TEMPERATURE; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 68049148618     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.10.8108     Document Type: Article

References (47)

1. Frei E, Cucchi CA, Rosowsky A, Tantravahi R, Bernal S, Ervin TJ, et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 1985; 82:2158-62.
2. Loehrer PJ, Einhorn LH. Drug five years later, Cisplatin. Ann Intern Med 1984; 100:704-13.
3. Pratt WR, Ruddon RW, Ensminger WD, Maybaum J. The anticancer drugs, 2nd edition, Oxford University Press, New York, USA 1994.
4. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay. Mutat Res 1987; 190:59-62.
5. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-9.
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
7. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996; 382:678-9.
8. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996; 93:13595-9.
9. El-Deiry WS. Transactivation of repair genes by BRCA1. Cancer Biol Ther 2002; 5:490-1.
10. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 1998; 95:2302-6.
11. Williamson EA, Dadmanesh F, Koeffler HP. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27 (Kip1). Oncogene 2002; 21:3199-206.
12. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88:265-75.
13. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 1997; 94:5605-10.
14. Ratanaphan A, Canyuk B, Wasiksiri S, Mahasawat P. In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin. Biochim Biophys Acta 2005; 1725:145-51.
15. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3rd edition, Cold Spring Habor Laboratory Press USA 2001.
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cell. Nucleic Acids Res 1988; 16:1215.
17. Marky LA, Breslauer KJ. Calculating thermodynamic data for transitions of any molecularity from equilibrium melting curves. Biopolymers 1987; 26:1601-20.
18. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001; 10:353-60.
19. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients. Cancer Res 1987; 47:3000-4.
20. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, et al. Early clinical studies with cis-diammine-1,1- cyclobutanedicarboxylateplatinum(II). Cancer Chemother Pharmacol 1982; 9:140-7.
21. Donahue BA, Augot M, Bellon SF, Treiber DK, Toney JH, Lippard SJ, et al. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 1990; 29:5872-80.
22. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985; 24:707-13.
23. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84:5024-8.
24. Hofr C, Brabec V. Thermal and thermodynamic properties of duplex DNA containing site-specific interstrand cross-link of antitumor cisplatin or its clinically ineffective trans isomer. J Biol Chem 2001; 276:9655-61.
25. Hofr C, Farrell N, Brabec V. Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex. Nucleic Acids Res 2001; 29:2034-40.
26. Poklar N, Pilch DS, Lippard SJ, Redding EA, Dunham SU, Breslauer KJ. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability and energetics of a 20-mer DNA duplex. Proc Natl Acad Sci USA 1996; 93:7606-11.
27. Hashiguchi K, Matsumoto Y, Yasui A. Recruitment of DNA repair synthesis machinery to sites of DNA damage/repair in living cells. Nucleic Acids Res 2007; 35:2913-23.
28. Jakupec MA, Galanski M, Keppler BK. Tumor-inhibiting platinum complexes: state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003; 146:1-53.
29. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005; 53:3-11.
30. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 upregulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58:1120-3.
31. Sheibani N, Jennerwein MM, Eastman A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 1989; 28:3120-4.
32. Corda Y, Job C, Anin MF, Leng M, Job D. Transcription by eukaryotic and prokaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diammine-dichloroplatinum(II). Biochemistry 1991; 30:222-30.
33. Lemaire MA, Schwartz A, Rahmouni AR, Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc Natl Acad Sci USA 1991; 88:1982-5.
34. Damsma GE, Alt A, Brueckner F, Carell T, Cramer P. Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nat Struct Biol 2007; 14:1127-33.
35. Evans GL, Gralla JD. Differential effects of cisplatin on the expression of chimeric marker genes in CV-1 cells. Biochem Pharmacol 1992; 44:107-19.
36. Cullinane C, Mazur SJ, Essigmann JM, Phillips DR, Bohr VA. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 1999; 38:6204-12.
37. Tornaletti S, Patrick SM, Turchi JJ, Hanawalt PC. Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. J Biol Chem 2003; 278:35791-7.
38. Hu YF, Miyake T, Ye Q, Li R. Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain. J Biol Chem 2000; 275:40910-5.
39. Miyake T, Hu YF, Yu DS, Li R. A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling. J Biol Chem 2000; 275:40169-73.
40. Schlegel BP, Green VJ, Ladias JA, Parvin JD. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10á in activated transcription. Proc Natl Acad Sci USA 2000; 97:3148-53.
41. Haile DT, Parvin JD. Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain. J Biol Chem 1999; 274:2113-7.
42. Jung Y, Lippard SJ. Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents. J Biol Chem 2003; 278:52084-92.
43. Jung Y, Lippard SJ. RNA polymerase II blockage by cisplatin-damaged DNA: Stability and polyubiquitylation of stalled polymerase. J Biol Chem 2006; 281:1361-70.
44. Laine JP, Egly JM. When transcription and repair meet: a complex system. Trends Genet 2006; 22:430-6.
45. Coin F, Frit P, Viollet B, Salles B, Egly JM. TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease. Mol Cell Biol 1998; 18:3907-14.
46. Vichi P, Coin F, Renaud JP, Vermeulen W, Hoeijmakers JH, Moras D, et al. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J 1997; 16:7444-56.
47. Zhai X, Beckmann H, Jantzen HM, Essigmann JM. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 1998; 37:16307-15.